*Short Courses require an additional registration fee. You do not need to be registered for the forum to attend*

This Short Course will be offering in a virtual format only

The implementation of the EU requirements for the use of Reference Safety Information (RSI) in determining expectedness of “suspected” serious adverse reactions (SARs) from clinical trials continues to be challenging. This half-day short course will be conducted in two parts. The first part will focus, at a high level, on the basic aspects of the EU Regulation and EU Guidance (including Q&A Documents) that govern the content, placement, use, and management of the Reference Safety Information and compare/contrast with the US FDA approach to assessing expectedness and causality to determine reportability of individual clinical trial cases. The second part will focus on practical aspects of implementing the regulations and guidance, criteria for updating the RSI, UK MHRA approach following Brexit and a review of acceptable and non-acceptable examples of the RSI.

Discount will be reflected on the last page of the cart.